Molecular Detection Technologies for Helicobacter pylori Antibiotic Resistance: Current Status and Clinical Implications.
- 1Shenzhen Institute for Drug Control Shenzhen Testing Center of Medical Devices, Shenzhen, 518057, P.R. China.
- 2Shenzhen Institute for Drug Control Shenzhen Testing Center of Medical Devices, Shenzhen, 518057, P.R. China. [email protected].
Abstract
Helicobacter pylori (H. pylori) infects approximately half of the global population and is closely linked to chronic gastritis, peptic ulcers, and gastric cancer. Antibiotic resistance has become a major global health concern with marked regional variations, severely undermining empirical treatment efficacy. Resistance mechanisms primarily involve target gene mutations, efflux pump overexpression, and altered membrane permeability. This review summarizes resistance mechanisms of commonly used antibiotics against H. pylori, along with diagnostic approaches ranging from phenotypic to molecular methods, the latter offering faster and more precise mutation detection, yet limited by high costs and invasive sampling. Treatment has shifted from clarithromycin-based triple therapy to bismuth-containing quadruple and potassium-competitive acid blocker-based regimens. However, susceptibility-guided therapy faces implementation barriers, and empirical regimens remain prevalent. Future directions emphasize affordable multiplex molecular platforms, resistance surveillance networks, artificial intelligence-driven predictive models, and non-antibiotic adjunctive strategies. Integrating molecular diagnostics with antimicrobial stewardship to transition from empirical to precision-based management is critical for improving eradication rates and curbing further resistance spread.
Related
- Advances in Research on the Genotype–Phenotype Correspondence of Antibiotic Resistance in Helicobacter pylori and Its Molecular Mechanisms: A Narrative Review
- Culture-free Helicobacter pylori genomics reveals within-host virulence heterogeneity and antibiotic resistance
- Knowledge and misconceptions about antibiotic use and antibiotic resistance among secondary school students in Riyadh, Saudi Arabia: implications for school- based antibiotic resistance education
- Antibiotic resistance profiles and molecular characteristics of Clostridioides difficile PCR ribotypes in patients with colorectal polyps
- Resistance to covalent Bruton's tyrosine kinase inhibitors in diffuse large B-cell lymphoma: Molecular mechanisms and therapeutic implications (Review)
BibTeX
@article{wang2026molecular,
title = {{Molecular Detection Technologies for Helicobacter pylori Antibiotic Resistance: Current Status and Clinical Implications.}},
author = {Zhenyu Wang and Jun Lin and Xuanni Zhang and Juan Yang and Yao Liu and Yuan Ji},
journal = {Current microbiology},
year = {2026},
month = oct,
doi = {10.1007/s00284-026-05136-1},
url = {https://europepmc.org/article/MED/42897307},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Molecular Detection Technologies for Helicobacter pylori Antibiotic Resistance: Current Status and Clinical Implications.
AU - Zhenyu Wang
AU - Jun Lin
AU - Xuanni Zhang
AU - Juan Yang
AU - Yao Liu
AU - Yuan Ji
PY - 2026
DA - 2026/10/19
JO - Current microbiology
DO - 10.1007/s00284-026-05136-1
UR - https://europepmc.org/article/MED/42897307
AB - Helicobacter pylori (H. pylori) infects approximately half of the global population and is closely linked to chronic gastritis, peptic ulcers, and gastric cancer. Antibiotic resistance has become a major global health concern with marked regional variations, severely undermining empirical treatment efficacy. Resistance mechanisms primarily involve target gene mutations, efflux pump overexpression, and altered membrane permeability. This review summarizes resistance mechanisms of commonly used antibiotics against H. pylori, along with diagnostic approaches ranging from phenotypic to molecular methods, the latter offering faster and more precise mutation detection, yet limited by high costs and invasive sampling. Treatment has shifted from clarithromycin-based triple therapy to bismuth-containing quadruple and potassium-competitive acid blocker-based regimens. However, susceptibility-guided therapy faces implementation barriers, and empirical regimens remain prevalent. Future directions emphasize affordable multiplex molecular platforms, resistance surveillance networks, artificial intelligence-driven predictive models, and non-antibiotic adjunctive strategies. Integrating molecular diagnostics with antimicrobial stewardship to transition from empirical to precision-based management is critical for improving eradication rates and curbing further resistance spread.
SN - 0343-8651
SN - 1432-0991
ER -